Literature DB >> 16619492

Chromosome 1 abnormalities in multiple myeloma.

Youna Marzin1, Déborah Jamet, Nathalie Douet-Guilbert, Frédéric Morel, Marie-Josée Le Bris, Patrick Morice, Jean-François Abgrall, Christian Berthou, Marc De Braekeleer.   

Abstract

Multiple myeloma (MM) is a malignancy of the terminally-differentiated B cells and accounts for 10% of all hematological malignancies. Chromosome 1 aberrations are frequently described, the short arm being preferentially involved in deletions and the long arm in gains. The abnormalities were identified in the bone marrow of 37 MM patients by conventional cytogenetics. Fluorescence in situ hybridization (FISH) was used to confirm the presence of the abnormalities and to better characterize them. Chromosome 1 abnormalities were grouped into 4 categories: balanced translocations, deletions, amplifications and jumping translocations (JT). Breakpoints involved in balanced translocations were randomly distributed. The smallest region of overlap for deletions was 1p11 --> 1p21 (present in 27% of the patients) and for gains 1q31 --> 1qter (present in 54% of the patients). The whole long arm was found to be the donor segment for the majority of patients with JT, the most frequent recipients being chromosomes 16 and 19. Our results share some similarities with those obtained for 143 published patients studied by FISH. Band 1p21 was found to be frequently deleted, leading to the assumption that a 1p deletion could lead to hemizygosity of at least 1 tumor suppressor gene. Two regions of 1q showed preferential gains: q12 to q22 and q31 to q42; these amplifications could induce the overexpression of 1 or more oncogenes. In conclusion, our results confirm that chromosome 1 abnormalities play an important role in the pathogenesis of multiple myeloma.

Entities:  

Mesh:

Year:  2006        PMID: 16619492

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  13 in total

1.  Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation.

Authors:  Gunjan L Shah; Heather Landau; Dory Londono; Sean M Devlin; Satyajit Kosuri; Alexander M Lesokhin; Nikoletta Lendvai; Hani Hassoun; David J Chung; Guenther Koehne; Suresh C Jhanwar; Ola Landgren; Ross Levine; Sergio A Giralt
Journal:  Leuk Lymphoma       Date:  2017-01-12

2.  C1orf35 contributes to tumorigenesis by activating c-MYC transcription in multiple myeloma.

Authors:  Sai-Qun Luo; De-Hui Xiong; Jiang Li; Guangdi Li; Yali Wang; Jia-Ming Zhang; Xiu-Fen Bu; Wei-Xin Hu; Jingping Hu
Journal:  Oncogene       Date:  2020-02-27       Impact factor: 9.867

3.  Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents.

Authors:  Smith Giri; Scott F Huntington; Rong Wang; Amer M Zeidan; Nikolai Podoltsev; Steven D Gore; Xiaomei Ma; Cary P Gross; Amy J Davidoff; Natalia Neparidze
Journal:  Blood Adv       Date:  2020-05-26

Review 4.  The Evolution of Prognostic Factors in Multiple Myeloma.

Authors:  Amr Hanbali; Mona Hassanein; Walid Rasheed; Mahmoud Aljurf; Fahad Alsharif
Journal:  Adv Hematol       Date:  2017-02-21

5.  Deletions of CDKN2C in multiple myeloma: biological and clinical implications.

Authors:  Paola E Leone; Brian A Walker; Matthew W Jenner; Laura Chiecchio; Gianpaolo Dagrada; Rebecca K M Protheroe; David C Johnson; Nicholas J Dickens; Jose Luis Brito; Monica Else; David Gonzalez; Fiona M Ross; Selina Chen-Kiang; Faith E Davies; Gareth J Morgan
Journal:  Clin Cancer Res       Date:  2008-10-01       Impact factor: 12.531

6.  Whole-genome optical mapping of bone-marrow myeloma cells reveals association of extramedullary multiple myeloma with chromosome 1 abnormalities.

Authors:  Eva Kriegova; Regina Fillerova; Jiri Minarik; Jakub Savara; Jirina Manakova; Anna Petrackova; Martin Dihel; Jana Balcarkova; Petra Krhovska; Tomas Pika; Petr Gajdos; Marek Behalek; Michal Vasinek; Tomas Papajik
Journal:  Sci Rep       Date:  2021-07-19       Impact factor: 4.379

7.  Translocation t(11;14) (q13;q32) and genomic imbalances in multi-ethnic multiple myeloma patients: a Malaysian study.

Authors:  Ivyna Bong Pau Ni; Ng Ching Ching; Chang Kian Meng; Zubaidah Zakaria
Journal:  Hematol Rep       Date:  2012-09-28

8.  Polyploidy in myelofibrosis: analysis by cytogenetic and SNP array indicates association with advancing disease.

Authors:  Nisha R Singh; Christine M Morris; Mary Koleth; Kelly Wong; Christopher M Ward; William S Stevenson
Journal:  Mol Cytogenet       Date:  2013-12-17       Impact factor: 2.009

9.  Identification of novel pathogenic copy number aberrations in multiple myeloma: the Malaysian context.

Authors:  Pau Ni Ivyna Bong; Ching Ching Ng; Kah Yuen Lam; Puteri Jamilatul Noor Megat Baharuddin; Kian Meng Chang; Zubaidah Zakaria
Journal:  Mol Cytogenet       Date:  2014-04-01       Impact factor: 2.009

10.  Abnormalities in Chromosomes 1q and 13 Independently Correlate With Factors of Poor Prognosis in Multiple Myeloma.

Authors:  Miyoung Kim; Young Su Ju; Eun Jin Lee; Hee Jung Kang; Han Sung Kim; Hyoun Chan Cho; Hyo Jung Kim; Jung Ah Kim; Dong Soon Lee; Young Kyung Lee
Journal:  Ann Lab Med       Date:  2016-11       Impact factor: 3.464

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.